Truseltiq (Infigratinib)

Truseltiq is a kinase inhibitor used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Recommended Dosage: The recommended dosage is 125 mg (one 100 mg capsule and one 25 mg capsule) orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs. 

Take Truseltiq capsules on an empty stomach at least one hour before or two hours after meal, at approximately the same time each day. Swallow capsules whole with a glass of water. Do not crush, chew, or dissolve capsules. 

In case a dose of Truseltiq is skipped/missed by ≥4 hours or if vomiting occurs, patients should resume the regular 

daily dose schedule the next day.

Mild and Moderate Renal Impairment: The recommended dose is 100 mg taken orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. 

Mild Hepatic Impairment: The recommended dose is 100 mg taken orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. 

Moderate Hepatic Impairment: The recommended dose is 75 mg taken orally once daily for 21 consecutive days followed by 7 days off therapy, in 28­ day cycles.

• Truseltiq capsules 25 mg can cause RPED, which may cause blurred vision. Perform an ophthalmic examination including OCT before the initiation of therapy, at 1 month, at 3 months, and then every three months thereafter during therapy. Refer patients for ophthalmic evaluation urgently for onset of visual signs/symptoms, and follow-up every three weeks until resolution or interruption of treatment.
• Infigratinib can cause hyperphosphatemia leading to soft tissue mineralization, vascular calcification, cutaneous calcinosis, non-uremic calciphylaxis, and myocardial calcification. Assess for hyperphosphatemia throughout therapy. Start phosphate lowering therapy when serum phosphate level is >5.5 mg/dL. For serum phosphate level >7.5 mg/dL, withhold Infigratinib and start phosphate lowering therapy. 
• Depending on findings in animal studies and its mechanism of action, Infigratinib can cause fetal harm if administered to a pregnant woman. Oral administration of infigratinib to pregnant animals during the period of organogenesis caused malformations, fetal growth retardation, and embryo-fetal death at maternal exposures lower than the human exposure based on area under the curve (AUC) at the clinical dose of 125 mg.
• Females of reproductive age should use effective contraception during treatment with Infigratinib and for at least 30 days after the last dose. Males with female partners of reproductive age should use effective contraception during treatment with Infigratinib and for 30 days after the final dose.

What documents are required to import TRUSELTIQ to India?

TRUSELTIQ (infigratinib) capsules can be imported by patients or government hospitals on behalf of patients.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the Government of India).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from a doctor.
• Import permit if applicable.

Is TRUSELTIQ available in India?

TRUSELTIQ (infigratinib capsules) is a prescription pharmaceutical drug that legally requires a medical prescription to be dispensed. Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability of Infigratinib in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.).
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

TRUSELTIQ can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of TRUSELTIQ (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Truseltiq price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source TRUSELTIQ (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Truseltiq®?

Infigratinib is the Generic Name for the trade name drug Truseltiq®.

What is the Manufacturer’s Name of Truseltiq®?

Truseltiq® is manufactured by BridgeBio Pharma, Inc.

Is Truseltiq® approved by the FDA?

Yes, Truseltiq® is approved by the FDA. Date of first/initial approval: May 28, 2021.

What is the dosage and form of Truseltiq® supplied?

Truseltiq® is supplied as Capsules: 25 mg and 100 mg for oral administration.

What are the most common side effects with Truseltiq®?

The most common side effects with Truseltiq® include: dry eye, nail toxicity, stomatitis, fatigue, alopecia, dry mouth, palmar-plantar erythrodysesthesia syndrome, arthralgia, constipation, abdominal pain, eyelash changes, dysgeusia, diarrhea, decreased appetite, dry skin, vision blurred, and vomiting.

How much does Truseltiq® cost in India?

The cost of Truseltiq® in India can vary. In order to procure this medication authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Truseltiq®?

Store Truseltiq® at a temperature of 20 to 25°C (68 to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).

Is it safe to buy Truseltiq® online from India?

Yes, you can buy Truseltiq® in India at the best price from Urgent Meds if Truseltiq® has not been approved or is not available in your country.